Economic evaluation of meningococcal serogroup B (MenB) vaccines: A systematic review

Nwogu, Ifechukwu B.; Jones, Matthew; Langley, Tessa

Abstract

Background:
Meningococcal serogroup B (MenB) has emerged as the leading cause of invasive meningococcal disease (IMD) in several countries following the release of effective vaccines against serogroups A, C, W, and Y. In 2013, however, the first multicomponent MenB vaccine (Bexsero®) was licensed in Europe.

Aim:
To review the evidence on the cost-effectiveness of vaccination against MenB.

Methods:
Searches were performed in MEDLINE, EMBASE, Web of Science, NHS EED, Econlit, Tufts CEA registry, and HTA. Three reviewers independently screened and selected studies. Using a narrative synthesis, studies were categorized by vaccination strategies. The quality of included studies was assessed using the Comparative Health Economics Evaluation Reporting Standards (CHEERS) checklist.

Results:
13 studies were included. Ten studies were conducted in the European region and three in the Americas. None of the vaccination strategies were considered cost-effective. Including herd effects improved value for money for MenB vaccines. Routine infant vaccination was the most effective short-term strategy, however, adolescent strategies offered the best value for money. Without herd immunity, routine infant vaccination had the lowest incremental cost-effectiveness ratio estimates.

Conclusion:
Routine MenB vaccination does not offer substantial value for money, mainly due to high vaccine costs and low disease incidence.

Citation

Nwogu, I. B., Jones, M., & Langley, T. (2021). Economic evaluation of meningococcal serogroup B (MenB) vaccines: A systematic review. Vaccine, 39(16), 2201-2213. https://doi.org/10.1016/j.vaccine.2021.02.049

• Journal Article Type: Article
• Acceptance Date: Feb 22, 2021
• Online Publication Date: Mar 18, 2021
• Publication Date: Apr 15, 2021
• Deposit Date: Mar 2, 2021
• Publicly Available Date: Mar 19, 2022
• Journal: Vaccine
• Print ISSN: 0264-410X
• Electronic ISSN: 0264-410X
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 39
• Issue: 16
• Pages: 2201-2213
• DOI: https://doi.org/10.1016/j.vaccine.2021.02.049
• Keywords: Public Health, Environmental and Occupational Health; General Immunology and Microbiology; Molecular Medicine; General Veterinary; Infectious Diseases
• Public URL: https://nottingham-repository.worktribe.com/output/5362993
• Publisher URL: https://www.sciencedirect.com/science/article/pii/S0264410X21002292